Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung cancer (NSCLC) undergoing robotic-assisted thoracic surgery. The main question it aims to answer is: Is downstaging after neoadjuvant chemo-immunotherapy associated with better surgical outcomes in patients with stage IIB-III NSCLC undergoing robotic-assisted surgery? Participants with resectable or potentially resectable stage IIB-III NSCLC who receive neoadjuvant chemo-immunotherapy as part of their routine clinical care and then undergo curative-intent robotic-assisted surgery will be prospectively enrolled from international centers. Clinical, operative, pathological, and postoperative outcome data will be collected, including R0 resection, the extent of resection, conversion to open surgery, postoperative complications, length of stay, readmission, and mortality.

NCT Number	NCT07528066
Lead Sponsor	Shanghai Chest Hospital Collaborators: The Affiliated Hospital of Qingdao University, Fujian Medical University Union Hospital, Guangdong Provincial People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Jiangsu Cancer Institute & Hospital, Shenzhen People's Hospital, Hopital Saint Joseph Marseille, University Hospital, Rouen, Azienda Ospedaliera Cosenza
Conditions	Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
Enrollment	200 participants
Start Date	2026-03-02
Primary Completion	2027-03-30 (estimated)
Study Completion	2027-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-14